More news articles

Research Partnership adds to its team

Dan Coffin joins the London headquarters as Director

BenevolentAI raises $115m to fund drug development

Its technology could cut the early stage drug discovery process by four years, says the company

Shire rebuffs Takeda bids, as Allergan bows out

Allergan doesn’t intend to make a formal offer following a dip in its share prices

Abeona Therapeutics names CEO

Carsten Thiel joins the biopharma from Alexion

Zelluna Immunotherapy appoints chief technology officer

Arjan Roozen will consolidate the biotech’s manufacturing strategy

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

Will also access Merck’s big-selling Neurobion and the Nasivin nasal decongestant range

Rigel and Ultragenyx claim approvals for rare drugs

Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively

Sobi poaches Pfizer’s Fredrick Wetterlundh

He joins the speciality healthcare group as head of human resources

VCCP Health strengthens client service team

Appoints two new account handlers

Amgen and Novartis migraine drug hits the mark again

Aimovig will become the first CGRP receptor-targeting drug if it reaches market

Good Relations win Nuffield Health account

The agency will combine Nuffield Health’s gym and hospital offerings

Sanofi sells European generics to Advent for $2.4bn

The deal will create a new, independent European generics company

Smith & Nephew name new CEO

Namal Nawana will also become an executive director

Targovax strengthens board of directors

Catherine Wheeler joins from Acetylon Pharmaceutical

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

Data shows the combo can improve survival compared to Pfizer’s Sutent

Merck’s Keytruda meets survival challenge in NSCLC

Data showed that almost 70% of patients on the combo were still alive after 12 months